Early therapy for undifferentiated arthritis can reduce the risk of progression to full-blown rheumatoid arthritis.
Reference1. Hilliquin S, Hugues B, Mitrovic S, Gossec L, Fautrel B. Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. Ann Rheum Dis. 2018;77:1099-1106.
Hilliquin and colleagues in Paris, France, found that treating undifferentiated arthritis early, before the diagnosis of rheumatoid arthritis (RA), may prevent established RA disease.1
Thumb through the slides for the details of the study and the take-home points for physicians.
(Image credit: ©CYCLONEPROJECT/Shutterstock.com)
ACR, American College of Rheumatology; bDMARDs, biologic disease-modifying anti-rheumatic drugs; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; EULAR, European League Against Rheumatism.